In a phase 2 trial of 150 patients with untreated metastatic triple-negative breast cancer, gemcitabine plus cisplatin did not significantly improve median PFS vs gemcitabine plus carboplatin (7.8 vs 7.0 months; HR 0.86, P=0.43); median OS was 20.3 vs 19.3 months.
RCTn = 150
Gong et al. A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer